[{"id":"4bf9de82-bc5d-4f41-96c1-1ff5dcf642d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672524","created_at":"2023-01-05T14:58:33.539Z","updated_at":"2024-07-02T16:35:09.423Z","phase":"Phase 2","brief_title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","source_id_and_acronym":"NCT05672524","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"}]